Hot of the press: new issue of BIOTECH Insight
The latest issue of BIOTECH Insight newsletter of Deutsche Börse in collaboration with BIOCOM AG is out, covering hot topics of the German biotech sector.
Algal enzyme synthesizes gasoline building blocks
An algal photoenzyme that synthesizes medium-chain hydrocarbons the building blocks of gasoline is set to boost industrial-scale production of biofuels.
Macomics licences macrophage modulator to Ono
Edinburgh-based immuno-oncology expert Macomics Ltd has partnered with Ono Pharmaceutical to develop a macrophage-targeting antibody targetting cancer.
mbiomics GmbH cashes in 13m in Series A financing
Munich-based microbiome therapeutics specialist mbiomics GmbH has raised 13m in the first closing of Series A round led by MIG Capital.
500 experts at the 7th AMR Conference in Basel
How to stop hard-to-diagnose, treatment-resistant microbial pathogens was discussed by experts from 13 countries at the 7th AMR Conference in Basel.
Vitestro raises 12m in Series A financing
With assets of 12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
European VCs join US$105m financing of US Mediar Thx
Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Iktos SA raises 15.5m in Series A financing
Paris-based AI-inspired drug discovery specialist Iktos SA has closed a 15.5m financing to expand its platform and kick-start the new CRO Iktos Robotics.
Oculis lists at Nasdaq through SPAC merger
The eye disease specialist Oculis Holding AG has been listed on Nasdaq following the merger of Oculis SA with European Biotech Acquisition Corp.
Confo Therapeutics and Lilly partner to advance CFTX-1554
Drug developer Confo Therapeutics and Eli Lilly & Company have inked a worldwide licensing agreement to co develop Confo’s neurophatic pain candidate CFTX-1554.